Plain-English translation of NCT07116915 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called HRS-9821 that you would inhale (breathe in) as a powder or liquid mist. The trial is checking whether this medication is safe and how your body handles it, first in healthy volunteers and then in people diagnosed with chronic obstructive pulmonary disease (COPD), a condition that makes it hard to breathe.
COPD is a serious lung disease that affects millions of people, and current treatments don't work well enough for everyone. This trial is exploring whether this new inhaled medication could offer a better way to help people breathe easier and manage their symptoms.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you qualify, you will either receive the new medication or a placebo (inactive treatment) by inhaling it either as a single dose or daily for 12 days. You'll have screening visits to check your heart and lung health, and then regular follow-up visits where the study team will monitor you for any side effects, take blood samples, and check your vital signs. The whole study will last several weeks to months depending on which group you're in.
AI-generated summary from trial data ยท Jun 2, 2026 ยท Not medical advice
China